Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • Our Leadership
    • Diversity, Equity, and Inclusion
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • Our Approach to Gene Therapy
    • Our Treatment Process
    • Our Pipeline
    • Clinical Trials
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers
  • stories

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Sarah Alspach

    Chief Communications Officer

    (857) 299-6198

    sarah.alspach@bluebirdbio.com

  • Jess Rowlands

    Senior Director, Product Communications

    (857) 299-6103

    jess.rowlands@bluebirdbio.com

Investor Contacts

  • Courtney O’Leary

    Investor Relations

    (978) 621-7347

    coleary@bluebirdbio.com

bluebird bio to Separate Oncology Business into Independent Company

  • Read more about bluebird bio to Separate Oncology Business into Independent Company

Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events in Group C of Phase 1/2 HGB-206 Clinical Study Presented at 62nd Annual ASH Meeting

  • Read more about Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events in Group C of Phase 1/2 HGB-206 Clinical Study Presented at 62nd Annual ASH Meeting

Long-Term Data for bluebird bio’s betibeglogene autotemcel (beti-cel) Gene Therapy Show Patients Across Ages and β-thalassemia Genotypes Achieve Transfusion Independence and Remain Free from Transfusions Up to Six Years Presented at 62nd ASH Meeting

  • Read more about Long-Term Data for bluebird bio’s betibeglogene autotemcel (beti-cel) Gene Therapy Show Patients Across Ages and β-thalassemia Genotypes Achieve Transfusion Independence and Remain Free from Transfusions Up to Six Years Presented at 62nd ASH Meeting

Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020

  • Read more about Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020

Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease

  • Read more about Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease

bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

  • Read more about bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

bluebird bio ASH Data Review Webcast

  • Read more about bluebird bio ASH Data Review Webcast

Barclays Gene Editing & Gene Therapy Summit

  • Read more about Barclays Gene Editing & Gene Therapy Summit

Cowen 2020 IO Next Summit

  • Read more about Cowen 2020 IO Next Summit

bluebird bio Announces November Investor Events

  • Read more about bluebird bio Announces November Investor Events

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Current page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Quick Links

  • Patients & Advocacy
  • Investors & Media
  • Careers
  • Contact Us

CONTACT INFO

info@bluebirdbio.com

clinicaltrials@bluebirdbio.com

investor@bluebirdbio.com

medinfo@bluebirdbio.com

Live - Terms & Privacy

  • Terms of Service
  • Privacy Policy
  • Cookie Notice
  • Sitemap
© 2022 bluebird bio, Inc. All Rights Reserved. Corp-US-00175 04/22

Live - Social Links